{
    "clinical_study": {
        "@rank": "99070", 
        "arm_group": [
            {
                "arm_group_label": "Arm A", 
                "arm_group_type": "Experimental", 
                "description": "AEB071 and MEK162 combined"
            }, 
            {
                "arm_group_label": "Arm B", 
                "arm_group_type": "Experimental", 
                "description": "MEK162 alone"
            }
        ], 
        "brief_summary": {
            "textblock": "A phase Ib dose-escalation study of the AEB071 and MEK162 combination in adult patients with\n      confirmed metastatic uveal melanoma.  Cohorts of 3-6 patients will be assessed for dose\n      limiting toxicities (DLTs) during Cycle 1 until the maximum tolerated dose (MTD) of the\n      combination therapy is determined. The MTD or Phase 2 Recommended Dose (P2RD) will be used\n      in a Phase II part of the study, which will enrol 55 patients each into two randomized\n      groups: the combination therapy or MEK162 alone.  The Phase II part will continue until\n      proof of concept is established.  Patients will continue treatment as long as clinical\n      benefit is seen and no limiting adverse toxicity is observed"
        }, 
        "brief_title": "A Phase Ib/II Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Uveal Melanoma", 
        "condition_browse": {
            "mesh_term": [
                "Melanoma", 
                "Uveal Neoplasms"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent\n\n          -  Male and female patients aged 18 years or older\n\n          -  A history of uveal (ocular) melanoma with biopsy-confirmed metastatic disease\n\n          -  Consent to providing 3 tumor biopsy samples throughout the course of the study\n\n          -  Presence of measurable disease\n\n          -  A WHO performance status of less than or equal to 1\n\n        Exclusion Criteria:\n\n          -  Presence of CNS lesions (stable lesions may be acceptable)\n\n          -  Previous or concurrent malignancy, other than basal cell or squamous cell carcinoma\n             of the skin: in situ carcinoma of the cervix, without evidence of recurrence for at\n             least 3 years; a primary malignancy completely resected and no evidence of recurrence\n             for at least 3 years\n\n          -  Adverse event from prior chemotherapy, radiotherapy or surgery that has not recovered\n             to CTCAE v4.03 Grade 1 or less, except for alopecia/sensory peripheral neuropathy,\n             which must be less than Grade 2\n\n          -  History or current evidence of retinal vein occlusion (RVO) or current risk factors\n             for RVO\n\n          -  Impaired cardiac function or clinically significant cardiac disease\n\n          -  Impaired GI function or disease that could interfere with the absorption of AEB071\n             and/or MEK162\n\n          -  Treatment with medicines or herbal supplements that are known inhibitors or inducers\n             of CYP3A4/5 and cannot be withdrawn prior to study treatment\n\n          -  Females of child-bearing potential who are unwilling or unable to use highly\n             effective means of contraception\n\n          -  Males who are unwilling or unable to use a condom during sexual intercourse\n\n          -  Prior exposure to a MEK or PKC inhibitor Other inclusion/exclusion criteria apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "125", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 21, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01801358", 
            "org_study_id": "CMEK162X2203"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A", 
                "description": "Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)", 
                "intervention_name": "AEB071", 
                "intervention_type": "Drug", 
                "other_name": "Sotrastaurin"
            }, 
            {
                "arm_group_label": [
                    "Arm A", 
                    "Arm B"
                ], 
                "description": "Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)", 
                "intervention_name": "MEK162", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Melanoma,", 
            "melanoma of the eye,", 
            "uveal,", 
            "MEK162,", 
            "AEB071"
        ], 
        "lastchanged_date": "December 10, 2013", 
        "location": [
            {
                "contact": {
                    "email": "betha_meyers@dfci.harvard.edu", 
                    "last_name": "Beth Meyers", 
                    "phone": "617-582-7116"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02115"
                    }, 
                    "name": "Dana Farber Cancer Institute Dept. Onc"
                }, 
                "investigator": {
                    "last_name": "Jason J. Luke", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "martinn@mskcc.org", 
                    "last_name": "Natasha Martin", 
                    "phone": "646-888-4339"
                }, 
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10021"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center Dept of Onc.."
                }, 
                "investigator": {
                    "last_name": "Gary K. Schwartz", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "IDS-Service.Pharmacy@jeffersonhospital.org", 
                    "last_name": "Linda Sailor", 
                    "phone": "215-955-9980"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19107-5098"
                    }, 
                    "name": "Thomas Jerfferson University Hospital SC"
                }, 
                "investigator": {
                    "last_name": "Takami Sato", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Westmead", 
                        "country": "Australia", 
                        "state": "New South Wales", 
                        "zip": "2145"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Paris", 
                        "country": "France", 
                        "zip": "75231"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "sebastian.bauer@uk.essen.de", 
                    "last_name": "Sebastien Bauer, M.D.", 
                    "phone": "+49 (0) 201-723-2014"
                }, 
                "facility": {
                    "address": {
                        "city": "Essen", 
                        "country": "Germany", 
                        "zip": "45147"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Padova", 
                        "country": "Italy", 
                        "state": "PD", 
                        "zip": "35100"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leiden", 
                        "country": "Netherlands", 
                        "zip": "2300 RC"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oslo", 
                        "country": "Norway", 
                        "zip": "NO-0424"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madrid", 
                        "country": "Spain", 
                        "zip": "28050"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom", 
                        "zip": "SW3 6JJ"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wirral", 
                        "country": "United Kingdom", 
                        "zip": "CH63 3JY"
                    }, 
                    "name": "Novartis Investigative Site"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Australia", 
                "France", 
                "Germany", 
                "Italy", 
                "Netherlands", 
                "Norway", 
                "Spain", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase Ib/II, Open-label, Multicenter Study of AEB071 and MEK162 in Adult Patients With Metastatic Uveal Melanoma", 
        "overall_contact": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone": "1-888-669-6682"
        }, 
        "overall_contact_backup": {
            "last_name": "Novartis Pharmaceuticals", 
            "phone_ext": "+41613241111"
        }, 
        "overall_official": {
            "affiliation": "Novartis Pharmaceuticals", 
            "last_name": "Novartis Pharmaceuticals", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "European Union: European Medicines Agency", 
                "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
                "United States: Food and Drug Administration", 
                "Australia: Department of Health and Ageing Therapeutic Goods Administration"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1/Phase 2", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "A DLT is defined as an adverse event or abnormal laboratory value as defined in the protocol that is assessed as unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first 28 days of treatment with AEB071and MEK162.", 
                "measure": "Phase I: dose limiting toxicity (DLT)", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 28 days of treatment with AEB071 and MEK162"
            }, 
            {
                "description": "The time from date of randomization to the date of event defined as the first documented progression or death due to any cause.", 
                "measure": "Phase II: Progression-Free Survival", 
                "safety_issue": "No", 
                "time_frame": "From first dose cycle 1, day 1 (C1D1) to time to progression up to 18 months from Last Patient First Visit (LPFV)"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01801358"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Duration from best response to confirmed disease progression", 
                "measure": "Duration of Response (Phase Ib and Phase II)", 
                "safety_issue": "No", 
                "time_frame": "From first dose (C1D1) to time to progression up to 18 months from LPFV"
            }, 
            {
                "description": "Best response recorded from the start of treatment until disease progression/recurrence (response is SD, PR or CR)", 
                "measure": "Best Overall Response (Phase Ib and Phase II)", 
                "safety_issue": "No", 
                "time_frame": "From first dose (C1D1) to time to progression up to 18 months from LPFV"
            }, 
            {
                "description": "The time from date of randomization to the date of event defined as the first documented progression or death due to any cause.", 
                "measure": "Progression-free survival (Phase Ib)", 
                "safety_issue": "No", 
                "time_frame": "From first dose (C1D1) to time to progression up to 18 months from LPFV"
            }, 
            {
                "description": "The duration of survival from LPFV until confirmed death due to any cause, whether on treatment or not", 
                "measure": "Overall survival", 
                "safety_issue": "No", 
                "time_frame": "From Last Patient First Visit (LPFV) to death or lost to follow-up up to 18 months from LPFV"
            }, 
            {
                "description": "Frequency of Adverse Events (AEs) and Serious Adverse Events (SAEs), as well as changes in laboratory values and electrocardiograms, dose interruptions, reductions and dose intensity", 
                "measure": "Safety and tolerability of AEB071 and MEK162 (Phase II)", 
                "safety_issue": "Yes", 
                "time_frame": "From consent to 30-days post-end-of-treatment"
            }, 
            {
                "description": "Determine blood concentrations and fit to standard PK parameters", 
                "measure": "Blood concentrations of AEB071, MEK162 and their active metabolites (Phase Ib)", 
                "safety_issue": "No", 
                "time_frame": "up to 28 days"
            }, 
            {
                "description": "Proportion of patients with a best overall response rate of CR or PR", 
                "measure": "Overall Response Rate (Phase Ib and Phase II)", 
                "safety_issue": "No", 
                "time_frame": "From first does (C1D1) to progression up to 18 months from LPFV"
            }
        ], 
        "source": "Novartis", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novartis Pharmaceuticals", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}